Mélanie Annoussamy1, Charlotte Lilien1, Teresa Gidaro1, Elena Gargaun1, Virginie Chê1, Ulrike Schara1, Andrea Gangfuß1, Adele D'Amico1, James J Dowling1, Basil T Darras1, Aurore Daron1, Arturo Hernandez1, Capucine de Lattre1, Jean-Michel Arnal1, Michèle Mayer1, Jean-Marie Cuisset1, Carole Vuillerot1, Stéphanie Fontaine1, Rémi Bellance1, Valérie Biancalana1, Ana Buj-Bello1, Jean-Yves Hogrel1, Hal Landy1, Laurent Servais2. 1. From I-Motion (M.A., C.L., T.G., E.G., V.C., L.S.), Institute of Myology, Paris, France; Paediatric Neurology and Neuromuscular Center (U.S., A.G.), University of Essen, Germany; Unit of Neuromuscular and Neurodegenerative Disorders (A. D'Amico), Department of Neurosciences, Bambino Gesu Children's Research Hospital IRCCS, Rome, Italy; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.), Hospital for Sick Children, Toronto, Canada; Boston Children's Hospital (B.T.D.), MA; Centre de Référence Neuromusculaire (A. Daron), CHR La Citadelle, Liège, Belgium; UCI Pediatrica (A.H.), Hospital Puerta del Mar, Cadiz, Spain; Centre de Référence Maladies Neuromusculaires Adulte (C.d.L.), Hôpital de la Croix-Rousse, Hospices Civils de Lyon; Service de Réanimation Polyvalente (J.-M.A.), Hôpital Sainte Musse, Toulon; Centre de Référence des Maladies Neuromusculaires d'Ile de France-Nord et Est (M.M.), Hôpital Armand Trousseau, Paris; Service de Neuropédiatrie Hôpital Roger Salengro (J.-M.C.), CHRU, Lille; Service de Rééducation Pédiatrique "L'Escale" (C.V., S.F.), Hôpital Mère Enfant, CHU-Lyon, France; CeRCa (R.B.), Hôpital Pierre-Zobda-Quitman, CHU de Martinique, Fort-de-France, Martinique; Laboratoire Diagnostic Génétique (V.B.), Nouvel Hôpital Civil, Strasbourg; Genethon (A.B.-B.), UMR S951 Inserm, Univ Evry, Université Paris Saclay, Evry; Neuromuscular Investigation Center (J.-Y.H.), Institute of Myology, Paris, France; and Valerion Therapeutics (H.L.), Concord, MA. 2. From I-Motion (M.A., C.L., T.G., E.G., V.C., L.S.), Institute of Myology, Paris, France; Paediatric Neurology and Neuromuscular Center (U.S., A.G.), University of Essen, Germany; Unit of Neuromuscular and Neurodegenerative Disorders (A. D'Amico), Department of Neurosciences, Bambino Gesu Children's Research Hospital IRCCS, Rome, Italy; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.), Hospital for Sick Children, Toronto, Canada; Boston Children's Hospital (B.T.D.), MA; Centre de Référence Neuromusculaire (A. Daron), CHR La Citadelle, Liège, Belgium; UCI Pediatrica (A.H.), Hospital Puerta del Mar, Cadiz, Spain; Centre de Référence Maladies Neuromusculaires Adulte (C.d.L.), Hôpital de la Croix-Rousse, Hospices Civils de Lyon; Service de Réanimation Polyvalente (J.-M.A.), Hôpital Sainte Musse, Toulon; Centre de Référence des Maladies Neuromusculaires d'Ile de France-Nord et Est (M.M.), Hôpital Armand Trousseau, Paris; Service de Neuropédiatrie Hôpital Roger Salengro (J.-M.C.), CHRU, Lille; Service de Rééducation Pédiatrique "L'Escale" (C.V., S.F.), Hôpital Mère Enfant, CHU-Lyon, France; CeRCa (R.B.), Hôpital Pierre-Zobda-Quitman, CHU de Martinique, Fort-de-France, Martinique; Laboratoire Diagnostic Génétique (V.B.), Nouvel Hôpital Civil, Strasbourg; Genethon (A.B.-B.), UMR S951 Inserm, Univ Evry, Université Paris Saclay, Evry; Neuromuscular Investigation Center (J.-Y.H.), Institute of Myology, Paris, France; and Valerion Therapeutics (H.L.), Concord, MA. l.servais@institut-myologie.org.
Abstract
OBJECTIVES: Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures. METHODS: We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor and respiratory functions over the first year of follow-up. The humoral immunity against adeno-associated virus serotype 8 was also monitored. RESULTS: Forty-five male patients aged 3.5 months to 56.8 years were enrolled between May 2014 and May 2017. Thirteen patients had a mild phenotype (no ventilation support), 7 had an intermediate phenotype (ventilation support less than 12 hours a day), and 25 had a severe phenotype (ventilation support 12 or more hours a day). Most strength and motor function assessments could be performed even in very weak patients. Motor Function Measure 32 total score, grip and pinch strengths, and forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures discriminated the 3 groups of patients. Disease history revealed motor milestone loss in several patients. Longitudinal data on 37 patients showed that the Motor Function Measure 32 total score significantly decreased by 2%. Of the 38 patients evaluated, anti-adeno-associated virus type 8 neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10. CONCLUSIONS: Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population. CLINICALTRIALSGOV IDENTIFIER: NCT02057705.
OBJECTIVES: Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures. METHODS: We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor and respiratory functions over the first year of follow-up. The humoral immunity against adeno-associated virus serotype 8 was also monitored. RESULTS: Forty-five male patients aged 3.5 months to 56.8 years were enrolled between May 2014 and May 2017. Thirteen patients had a mild phenotype (no ventilation support), 7 had an intermediate phenotype (ventilation support less than 12 hours a day), and 25 had a severe phenotype (ventilation support 12 or more hours a day). Most strength and motor function assessments could be performed even in very weak patients. Motor Function Measure 32 total score, grip and pinch strengths, and forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures discriminated the 3 groups of patients. Disease history revealed motor milestone loss in several patients. Longitudinal data on 37 patients showed that the Motor Function Measure 32 total score significantly decreased by 2%. Of the 38 patients evaluated, anti-adeno-associated virus type 8 neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10. CONCLUSIONS: Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population. CLINICALTRIALSGOV IDENTIFIER: NCT02057705.
Authors: Christopher R Pierson; Ashley N Dulin-Smith; Ashley N Durban; Morgan L Marshall; Jordan T Marshall; Andrew D Snyder; Nada Naiyer; Jordan T Gladman; Dawn S Chandler; Michael W Lawlor; Anna Buj-Bello; James J Dowling; Alan H Beggs Journal: Hum Mol Genet Date: 2011-11-07 Impact factor: 6.150
Authors: N S Thomas; H Williams; G Cole; K Roberts; A Clarke; S Liechti-Gallati; S Braga; A Gerber; C Meier; H Moser Journal: J Med Genet Date: 1990-05 Impact factor: 6.318
Authors: I Vandersmissen; V Biancalana; L Servais; J J Dowling; G Vander Stichele; S Van Rooijen; L Thielemans Journal: Neuromuscul Disord Date: 2018-07-01 Impact factor: 4.296
Authors: Richard S Finkel; Claudia A Chiriboga; Jiri Vajsar; John W Day; Jacqueline Montes; Darryl C De Vivo; Mason Yamashita; Frank Rigo; Gene Hung; Eugene Schneider; Daniel A Norris; Shuting Xia; C Frank Bennett; Kathie M Bishop Journal: Lancet Date: 2016-12-07 Impact factor: 79.321
Authors: Richard S Finkel; Michael P McDermott; Petra Kaufmann; Basil T Darras; Wendy K Chung; Douglas M Sproule; Peter B Kang; A Reghan Foley; Michelle L Yang; William B Martens; Maryam Oskoui; Allan M Glanzman; Jean Flickinger; Jacqueline Montes; Sally Dunaway; Jessica O'Hagen; Janet Quigley; Susan Riley; Maryjane Benton; Patricia A Ryan; Megan Montgomery; Jonathan Marra; Clifton Gooch; Darryl C De Vivo Journal: Neurology Date: 2014-07-30 Impact factor: 9.910
Authors: Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay Journal: Nat Med Date: 2006-02-12 Impact factor: 53.440
Authors: Stacha F I Reumers; Frederik Braun; Jennifer E Spillane; Johann Böhm; Maartje Pennings; Meyke Schouten; Anneke J van der Kooi; A Reghan Foley; Carsten G Bönnemann; Erik-Jan Kamsteeg; Corrie E Erasmus; Ulrike Schara-Schmidt; Heinz Jungbluth; Nicol C Voermans Journal: Neurology Date: 2021-05-19 Impact factor: 11.800
Authors: Robert J Graham; Francesco Muntoni; Imelda Hughes; Sabrina W Yum; Nancy L Kuntz; Michele L Yang; Barry J Byrne; Suyash Prasad; Rachel Alvarez; Casie A Genetti; Tmirah Haselkorn; Emma S James; Laurie B LaRusso; Mojtaba Noursalehi; Salvador Rico; Alan H Beggs Journal: Arch Dis Child Date: 2019-09-04 Impact factor: 3.791
Authors: Eve Fouarge; Arnaud Monseur; Bruno Boulanger; Mélanie Annoussamy; Andreea M Seferian; Silvana De Lucia; Charlotte Lilien; Leen Thielemans; Khazal Paradis; Belinda S Cowling; Chris Freitag; Bradley P Carlin; Laurent Servais Journal: Orphanet J Rare Dis Date: 2021-01-06 Impact factor: 4.123
Authors: Jerry R Mendell; Samiah A Al-Zaidy; Louise R Rodino-Klapac; Kimberly Goodspeed; Steven J Gray; Christine N Kay; Sanford L Boye; Shannon E Boye; Lindsey A George; Stephanie Salabarria; Manuela Corti; Barry J Byrne; Jacques P Tremblay Journal: Mol Ther Date: 2020-12-10 Impact factor: 11.454
Authors: Sandra Donkervoort; Payam Mohassel; Lucia Laugwitz; Maha S Zaki; Erik-Jan Kamsteeg; Reza Maroofian; Katherine R Chao; Corien C Verschuuren-Bemelmans; Veronka Horber; Annemarie J M Fock; Riley M McCarty; Minal S Jain; Victoria Biancavilla; Grace McMacken; Matthew Nalls; Nicol C Voermans; Hasnaa M Elbendary; Molly Snyder; Chunyu Cai; Tanya J Lehky; Valentina Stanley; Susan T Iannaccone; A Reghan Foley; Hanns Lochmüller; Joseph Gleeson; Henry Houlden; Tobias B Haack; Rita Horvath; Carsten G Bönnemann Journal: Am J Med Genet A Date: 2020-08-10 Impact factor: 2.578